| Name | Title | Contact Details |
|---|---|---|
William Blake |
Chief Technology Officer | Profile |
Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.
We offer a solution to unscooped dog waste. Using our DNA Dog Waste Management program, more than 7,000 communities worldwide have successfully eliminated unscooped dog poop, leading to increased resident satisfaction and an enhanced pet experience. Clients report a 95% reduction in pet waste once our service is implemented because PooPrints is the only foolproof accountability method.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.